SciELO - Scientific Electronic Library Online

 
vol.9 número3Abordagem das Alterações do Olfato em Doentes Recuperados da COVID-19Reconciliação Terapêutica: Um Processo Complexo índice de autoresíndice de materiabúsqueda de artículos
Home Pagelista alfabética de revistas  

Servicios Personalizados

Revista

Articulo

Indicadores

Links relacionados

  • No hay articulos similaresSimilares en SciELO

Compartir


Gazeta Médica

versión impresa ISSN 2183-8135versión On-line ISSN 2184-0628

Resumen

FIGUEIREDO, Carlos M.; FREITAS, Diogo  y  FERREIRA, Maria do Céu. Persistent Sexual Dysfunction and Selective Serotonin Reuptake Inhibitors: Myth or Reality?. Gaz Med [online]. 2022, vol.9, n.3, pp.230-239.  Epub 30-Sep-2022. ISSN 2183-8135.  https://doi.org/10.29315/gm.v1i1.572.

Selective serotonin reuptake inhibitors antidepressants are psychopharmaceuticals frequently used in clinical practice in the fields of General Practice and Psychiatry for the treatment of depressive and anxiety disorders. The high prescription of this class of antidepressants results from their profile of efficacy, safety and tolerability.

It is clinically consensual that this pharmacological class can interfere with the various phases of the sexual response during antidepressant treatment. However, more and more cases have been reported in the literature, in which sexual dysfunction is not reversible after discontinuation of the drug, configuring a new persistent clinical entity, whose pathophysiological substrate is currently under intense scientific investigation. Reviewing the recent published literature in this matter and raising awareness of physicians about this new entity reveals itself as a priority with potential implications, particularly on the approach of psychiatric pathologies so prevalent in the current society.

Palabras clave : Serotonin Uptake Inhibitors/adverse effect; Sexual Dysfunction, Physiological/chemically induced.

        · resumen en Portugués     · texto en Portugués     · Portugués ( pdf )